Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies
Authors:
Open Access
- 18 September 2017
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 28 (suppl_5) , v482